Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein.
Arsenic exposure in humans causes a number of toxic manifestations in the skin including cutaneous neoplasm. However, the mechanism of these alterations remains elusive. Here, we provide novel observations that arsenic induced Hippo signaling pathway in the murine skin. This pathway plays crucial roles in determining organ size during the embryonic development and if aberrantly activated in adults, contributes to the pathogenesis of epithelial neoplasm. Arsenic treatment enhanced phosphorylation-dependent activation of LATS1 kinase and other Hippo signaling regulatory proteins Sav1 and MOB1. Phospho-LATS kinase is known to catalyze the inactivation of a transcriptional co-activator, Yap. However, in arsenic-treated epidermis, we did not observed its inactivation. Thus, as expected, unphosphorylated-Yap was translocated to the nucleus in arsenic-treated epidermis. Yap by binding to the transcription factors TEADs induces transcription of its target genes. Consistently, an up-regulation of Yap-dependent target genes Cyr61, Gli2, Ankrd1 and Ctgf was observed in the skin of arsenic-treated mice. Phosphorylated Yap is important in regulating tight and adherens junctions through its binding to αCatenin. We found disruption of these junctions in the arsenic-treated mouse skin despite an increase in αCatenin. These data provide evidence that arsenic-induced canonical Hippo signaling pathway and Yap-mediated disruption of tight and adherens junctions are independently regulated. These effects together may contribute to the carcinogenic effects of arsenic in the skin.
Department of Dermatology and Skin Diseases Research Center, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
Changzhao
C
Li
Ritesh K
RK
Srivastava
Craig A
CA
Elmets
Farrukh
F
Afaq
Mohammad
M
Athar
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D001151:Arsenic / Q000009:adverse effects*; D018797:Cell Cycle Proteins; D000090683:Hippo Signaling Pathway; D051379:Mice; D008812:Mice, Hairless; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D012867:Skin / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D015533:Transcriptional Activation; D015854:Up-Regulation / Q000187:drug effects; D000091102:YAP-Signaling Proteins
D048868:Adaptor Proteins, Signal Transducing; D018797:Cell Cycle Proteins; D010750:Phosphoproteins; D000091102:YAP-Signaling Proteins; C486223:Yap1 protein, mouse; D017346:Protein Serine-Threonine Kinases; D001151:Arsenic
AMOTL1; Angiomotin-like 1; Arsenic; BCC; Carcinogenesis; Hippo signaling pathway; LATS1/2; MOB kinase activator 1A; MOB1; Mst1/2; SCC; Salvador homolog 1; Sav1; TAZ; TEAD; Tea-domain; Yap; Yes-associated protein; basal cell carcinoma; large tumor suppressor kinase 1/2; mammalian STE20-like kinase 1/2; squamous cell carcinoma; transcriptional co-activator with PDZ-binding motif